Table 2 Presenting and post-loading VA based on distribution of ERF at visit 4.

From: Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3

ERF at visit 4

Baseline Mean VA (SD)

Post-loading (Visit 4)

Mean VA (SD)

Adjusted Mean VA (SE)a

ERF

58.1 (SD 14.8)

61.3 (16.5)

61.7 (SE 0.35)

No ERF

57.9 (SD 14.3)

64.4 (16.0)

63.4 (SE 0.36)

eSRF (±eIRF)

59.5 (SD 14.5)

63.2 (13.9)

62.1 (SE 0.41)

eSRF only

61.5 (SD 13.4)

65.2 (12.8)

62.7 (SE 0.45)

No eSRF

57.1 (SD 14.5)

62.1 (16.0)

62.8 (SE 0.32)

eIRF (±eSRF)

53.6 (SD 15.5)

57.2 (16.4)

60.3 (SE 0.56)

eIRF only

54.0 (SD 15.0)

57.6 (17.0)

60.4 (SE 0.71)

No eIRF

59.2 (SD 14.0)

64.0 (14.6)

63.2 (SE 0.29)

  1. ERF early residual fluid, eSRF early subretinal fluid, eIRF early intraretinal fluid.
  2. aGEE model with visit 4 visual acuity as the outcome and adjusted for baseline visual acuity.
Back to article page